The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of ...
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's ...
GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing ...
GSK is taking legal action against US biotech firm AnaptysBio, which it accuses of a 'material breach' of contractual ...
AnaptysBio (ANAB) shares lost ~11% in the premarket on Friday after the U.S. drugmaker and its partner Tesaro, a subsidiary ...
Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...
The litigation centers on Jemperli, a drug used to treat some forms of endometrial cancer. Anaptys originally discovered the drug and licensed it to Tesaro as part of a broader collaboration agreement ...
As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback